Skip to main content

Estimado (a) Dr. (a),

Le invitamos a ver la siguiente entrevista “Eficacia de iDegLira sobre la variabilidad glucémica y las metas de control”.

Por la Dra. Ana Rosa Escobedo Ortiz. Especialista en Endocrinología. Hospital General Dr. Miguel Silva. Cédula: 7187335.

Y la Dra. Paloma Almeda Valdés. Especialista en Endocrinología. Departamento de Endocrinología y Metabolismo. Unidad de investigación de Enfermedades Metabólicas, INCMNSZ. Cédula 3272414.



  1. Jonassen I, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012 Aug;29(8):2104-14.
  2. Kalra S, et al. Managing insulin resistance: role of liraglutide. Clin Pharmacol. 2010;2:131-4.
  3. Steensgaard DB, et al. The molecular basis for the delayed absorption of the once daily human GLP-1 analogue: liraglutide [abstract nr 552-P]. Diabetes. 2008;57 Suppl 1:A164.
  4. Skolnik N, et al. Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know. Clin Diabetes. 2018 Apr;36(2):174-182.
  5. Penckofer S, et al. Does glycemic variability impact mood and quality of life? Diabetes Technol Ther. 2012 Apr;14(4):303-10.
  6. Heise T, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012 Sep;14(9):859-64.
  7. Lu J, et al. Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes. Diabetes Care. 2018 Nov;41(11):2370-2376.
  8. Beck RW, et al. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care. 2019 Mar;42(3):400-405.
  9. Lingvay I, et al. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial. JAMA. 2016 Mar 1;315(9):898-907.
  10. What is Time in Range? Abril 2022. 
  11. Aroda VR, et al. Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019 Aug;7(8):596-605.
  12. Gough SCL, et al. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial. Diabetes Obes Metab. 2015 Oct;17(10):965-73. 
  13. Buse JB, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care. 2014 Nov;37(11):2926-33.
  14. Linjawi S, et al. The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial. Diabetes Ther. 2017 Feb;8(1):101-114.
  15. Rodbard HW, et al. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial. Diabet Med. 2017 Feb;34(2):189-196.
  16. Harris SB, et al. Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial. Diabetes Obes Metab. 2017 Jun;19(6):858-865.
  17. Billings LK, et al. Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial. Diabetes Care. 2018 May;41(5):1009-1016.
  18. Philis-Tsimikas A, et al. Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2019 Jun;21(6):1399-1408.
  19. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007 May;132(6):2131-57.
  20. Niswender KD. Basal Insulin: Beyond Glycemia. Postgrad Med. 2011 Jul;123(4):27-37.
  21. Carris NW, et al. Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations. Drugs. 2014 Dec;74(18):2141-52.
  22. Guigliano D, et al. Efficacy of insulin analogs in achieving the hemoglobin A1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Care. 2011 Feb;34(2):510-7.  
  23. Hammer M, et al. Costs of managing severe hypoglycaemia in three European countries. J Med Econ. 2009;12(4):281-90. 
  24. Peyrot M, et al. Epidemiology and correlates of weight worry in the multinational Diabetes Attitudes, Wishes and Needs study. Curr Med Res Opin. 2009 Aug;25(8):1985-93. 
  25. Peyrot M, et al. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012 May;29(5):682-9.
  26. Freemantle N, et al. IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy. Diabetes Ther. 2015 Dec;6(4):573-591.



Material desarrollado con fines de educación médica continua.

Material exclusivo para profesionales de la salud.

La información aquí presentada es opinión del ponente.

Código interno de aprobación: MX22NNM00123.

Leave a Reply